{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T06:58:20Z","timestamp":1791874700143,"version":"4.3.4"},"reference-count":57,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,7,1]],"date-time":"2017-07-01T00:00:00Z","timestamp":1498867200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,7,1]],"date-time":"2017-07-01T00:00:00Z","timestamp":1498867200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","maturitas.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Maturitas"],"published-print":{"date-parts":[[2017,7]]},"DOI":"10.1016\/j.maturitas.2017.04.008","type":"journal-article","created":{"date-parts":[[2017,4,14]],"date-time":"2017-04-14T22:16:52Z","timestamp":1492208212000},"page":"23-30","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":119,"special_numbering":"C","title":["Drug holidays from bisphosphonates and denosumab in postmenopausal osteoporosis: EMAS position statement"],"prefix":"10.1016","volume":"101","author":[{"given":"Panagiotis","family":"Anagnostis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stavroula A.","family":"Paschou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gesthimani","family":"Mintziori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iuliana","family":"Ceausu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Herman","family":"Depypere","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene","family":"Lambrinoudaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alfred","family":"Mueck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Faustino R.","family":"P\u00e9rez-L\u00f3pez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margaret","family":"Rees","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Levent M.","family":"Senturk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tommaso","family":"Simoncini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John C.","family":"Stevenson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Petra","family":"Stute","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florence A.","family":"Tr\u00e9mollieres","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dimitrios G.","family":"Goulis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.maturitas.2017.04.008_bib0005","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1007\/s00198-007-0540-8","article-title":"Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy","volume":"19","author":"Russell","year":"2008","journal-title":"Osteoporos. Int."},{"key":"10.1016\/j.maturitas.2017.04.008_bib0010","doi-asserted-by":"crossref","first-page":"2272","DOI":"10.1210\/jc.2012-1027","article-title":"Benefits and risks of bisphosphonate therapy for osteoporosis","volume":"97","author":"Khosla","year":"2012","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.maturitas.2017.04.008_bib0015","doi-asserted-by":"crossref","first-page":"1871","DOI":"10.1210\/jc.2011-3060","article-title":"Clinical review. comparative effectiveness of drug treatments to prevent fragility fractures: a systematic review and network meta-analysis","volume":"97","author":"Murad","year":"2012","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.maturitas.2017.04.008_bib0020","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1056\/NEJMoa0809493","article-title":"FREEDOM trial, denosumab for prevention of fractures in postmenopausal women with osteoporosis","volume":"361","author":"Cummings","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.maturitas.2017.04.008_bib0025","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1002\/jbmr.2405","article-title":"Diagnosis and management of osteonecrosis of the jaw: a systematic review and international consensus","volume":"30","author":"Khan","year":"2015","journal-title":"Bone Miner. Res."},{"key":"10.1016\/j.maturitas.2017.04.008_bib0030","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1177\/0022034510397196","article-title":"Risk factors for osteonecrosis of the jaws: a case-control study from the CONDOR dental PBRN","volume":"90","author":"Barasch","year":"2011","journal-title":"J. Dent. Res."},{"key":"10.1016\/j.maturitas.2017.04.008_bib0035","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/jbmr.1998","article-title":"Atypical subtrochanteric and diaphyseal femoral fractures: a second report of a task force of the American Society for Bone and Mineral Research","volume":"29","author":"Shane","year":"2014","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.maturitas.2017.04.008_bib0040","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1002\/jbmr.1893","article-title":"Bisphosphonates and risk of subtrochanteric, femoral shaft, and atypical femur fracture: a systematic review and meta-analysis","volume":"28","author":"Gedmintas","year":"2013","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.maturitas.2017.04.008_bib0045","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1093\/fampra\/cmu088","article-title":"Increased risk for atypical fractures associated with bisphosphonate use","volume":"32","author":"Lee","year":"2015","journal-title":"Fam. Pract."},{"key":"10.1016\/j.maturitas.2017.04.008_bib0050","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1001\/archinternmed.2012.1796","article-title":"Increasing occurrence of atypical femoral fractures associated with bisphosphonate use","volume":"172","author":"Meier","year":"2012","journal-title":"Arch. Intern. Med."},{"key":"10.1016\/j.maturitas.2017.04.008_bib0055","doi-asserted-by":"crossref","first-page":"2773","DOI":"10.1007\/s00198-015-3234-7","article-title":"The effect of 8 or 5 years of denosumab treatment in postmenopausal women with osteoporosis: results from the FREEDOM Extension study","volume":"26","author":"Papapoulos","year":"2015","journal-title":"Osteopor. Int."},{"key":"10.1016\/j.maturitas.2017.04.008_bib0060","doi-asserted-by":"crossref","first-page":"1728","DOI":"10.1056\/NEJMoa1010650","article-title":"Bisphosphonate use and atypical fractures of the femoral shaft","volume":"364","author":"Schilcher","year":"2011","journal-title":"N. Engl. J. Med"},{"key":"10.1016\/j.maturitas.2017.04.008_bib0065","doi-asserted-by":"crossref","first-page":"b2700","DOI":"10.1136\/bmj.b2700","article-title":"The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration","volume":"339","author":"Liberati","year":"2009","journal-title":"BMJ"},{"key":"10.1016\/j.maturitas.2017.04.008_bib0070","doi-asserted-by":"crossref","first-page":"2927","DOI":"10.1001\/jama.296.24.2927","article-title":"Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial.; FLEX research group","volume":"296","author":"Black","year":"2006","journal-title":"JAMA"},{"key":"10.1016\/j.maturitas.2017.04.008_bib0075","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1056\/NEJMoa030897","article-title":"Ten years' experience with alendronate for osteoporosis in postmenopausal women","volume":"350","author":"Bone","year":"2004","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.maturitas.2017.04.008_bib0080","first-page":"1492","article-title":"Alendronate in early postmenopausal women: effects on bone mass during long-term treatment and after withdrawal. Alendronate osteoporosis prevention study group","volume":"85","author":"Ravn","year":"2000","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.maturitas.2017.04.008_bib0085","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/S8756-3282(03)00112-1","article-title":"Alendronate has a residual effect on bone mass in postmenopausal Danish women up to 7 years after treatment withdrawal","volume":"33","author":"Bagger","year":"2003","journal-title":"Bone"},{"key":"10.1016\/j.maturitas.2017.04.008_bib0090","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1097\/01.GME.0000123641.76105.B5","article-title":"Early Postmenopausal Intervention Cohort Study Group Changes in bone density and turnover after alendronate or estrogen withdrawal","volume":"11","author":"Wasnich","year":"2004","journal-title":"Menopaus"},{"key":"10.1016\/j.maturitas.2017.04.008_bib0095","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1002\/jbmr.11","article-title":"FLEX Research Group, Efficacy of continued alendronate for fractures in women with and without prevalent vertebral fracture: the FLEX trial","volume":"25","author":"Schwartz","year":"2010","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.maturitas.2017.04.008_bib0100","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1002\/jbmr.1494","article-title":"The effect of 3 versus 6 years of zoledronic acid treatment of osteoporosis: a randomized extension to the HORIZON-pivotal fracture trial (PFT)","volume":"27","author":"Black","year":"2012","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.maturitas.2017.04.008_bib0105","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1002\/jbmr.2442","article-title":"The effect of 6 versus 9 years of zoledronic acid treatment in osteoporosis: a randomized second extension to the HORIZON-pivotal fracture trial (PFT)","volume":"30","author":"Black","year":"2015","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.maturitas.2017.04.008_bib0110","doi-asserted-by":"crossref","first-page":"4546","DOI":"10.1210\/jc.2014-1971","article-title":"Reassessment of fracture risk in women after 3 years of treatment with zoledronicacid: when is it reasonable to discontinue treatment?","volume":"99","author":"Cosman","year":"2014","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.maturitas.2017.04.008_bib0115","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1007\/s00198-007-0460-7","article-title":"Fracture risk remains reduced one year after discontinuation of risedronate","volume":"19","author":"Watts","year":"2008","journal-title":"Osteopor. Int."},{"key":"10.1016\/j.maturitas.2017.04.008_bib0120","doi-asserted-by":"crossref","first-page":"3367","DOI":"10.1210\/jc.2011-0412","article-title":"Effect of stopping risedronate after long-term treatment on bone turnover","volume":"96","author":"Eastell","year":"2011","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.maturitas.2017.04.008_bib0125","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1016\/S0278-2391(03)00720-1","article-title":"Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic","volume":"61","author":"Marx","year":"2003","journal-title":"J. Oral Maxillofac. Surg."},{"key":"10.1016\/j.maturitas.2017.04.008_bib0130","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1359\/jbmr.0707onj","article-title":"Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research","volume":"22","author":"Khosla","year":"2007","journal-title":"J. Bone Miner. Res."},{"issue":"March (7)","key":"10.1016\/j.maturitas.2017.04.008_bib0135","doi-asserted-by":"crossref","first-page":"43399","DOI":"10.1038\/srep43399","article-title":"Long-term effects of bisphosphonate therapy: perforations, microcracks and mechanical properties","volume":"6","author":"Ma","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.maturitas.2017.04.008_bib0140","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1056\/NEJMc1403799","article-title":"Risk of atypical femoral fracture during and after bisphosphonate use","volume":"371","author":"Schilcher","year":"2014","journal-title":"New Engl. J. Med."},{"key":"10.1016\/j.maturitas.2017.04.008_bib0145","doi-asserted-by":"crossref","first-page":"297","DOI":"10.2106\/JBJS.K.01181","article-title":"Bisphosphonates and nonhealing femoral fractures: analysis of the FDA Adverse Event Reporting System (FAERS) and international safety efforts: a systematic review from the Research on Adverse Drug Events And Reports (RADAR) project","volume":"95","author":"Edwards","year":"2013","journal-title":"J. Bone Jt. Surg."},{"key":"10.1016\/j.maturitas.2017.04.008_bib0150","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1097\/RHU.0000000000000170","article-title":"Bisphosphonates and hip and nontraumatic subtrochanteric femoral fractures in the veterans health administration","volume":"20","author":"Safford","year":"2014","journal-title":"J. Clin. Rheumatol."},{"key":"10.1016\/j.maturitas.2017.04.008_bib0155","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1007\/s00198-010-1453-5","article-title":"Subtrochanteric fractures after long-term treatment with bisphosphonates: a european society on clinical and economic aspects of osteoporosis and osteoarthritis, and international osteoporosis foundation working group report","volume":"22","author":"Rizzoli","year":"2011","journal-title":"Osteoporos. Int."},{"key":"10.1016\/j.maturitas.2017.04.008_bib0160","first-page":"346","article-title":"Alendronate and risedronate: reports of severe bone, joint, and muscle pain","volume":"165","author":"Wysowski","year":"2005","journal-title":"Arch. Int. Med."},{"key":"10.1016\/j.maturitas.2017.04.008_bib0165","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1056\/NEJMoa067312","article-title":"Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis","volume":"356","author":"Black","year":"2007","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.maturitas.2017.04.008_bib0170","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1007\/s00198-011-1546-9","article-title":"Alendronate and atrial fibrillation: a meta-analysis of randomized placebo-controlled clinical trials","volume":"23","author":"Barrett-Connor","year":"2012","journal-title":"Osteoporos. Int."},{"key":"10.1016\/j.maturitas.2017.04.008_bib0175","doi-asserted-by":"crossref","first-page":"219","DOI":"10.2165\/00002018-200932030-00004","article-title":"Bisphosphonates and atrial fibrillation: systematic review and meta-analysis","volume":"32","author":"Loke","year":"2009","journal-title":"Drug Saf."},{"key":"10.1016\/j.maturitas.2017.04.008_bib0180","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1007\/s00198-011-1608-z","article-title":"Use of bisphosphonate and risk of atrial fibrillation in older women with osteoporosis","volume":"23","author":"Rhee","year":"2012","journal-title":"Osteoporos. Int."},{"key":"10.1016\/j.maturitas.2017.04.008_bib0185","doi-asserted-by":"crossref","first-page":"e007133","DOI":"10.1136\/bmjopen-2014-007133","article-title":"Bisphosphonates and evidence for association with esophageal and gastric cancer: a systematic review and meta-analysis","volume":"5","author":"Wright","year":"2015","journal-title":"BMJ Open"},{"key":"10.1016\/j.maturitas.2017.04.008_bib0190","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1097\/GME.0000000000000480","article-title":"Effects of long-term risedronate treatment on serum ferritin levels in postmenopausal women with osteoporosis: the impact of cardiovascular risk factor load","volume":"23","author":"Feldbrin","year":"2016","journal-title":"Menopause"},{"key":"10.1016\/j.maturitas.2017.04.008_bib0195","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1056\/NEJMoa030897","article-title":"Ten years' experience with alendronate for osteoporosis in postmenopausal women","volume":"350","author":"Bone","year":"2004","journal-title":"New Engl. J. Med."},{"key":"10.1016\/j.maturitas.2017.04.008_bib0200","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1007\/s00223-004-0286-7","article-title":"Seven years of treatment with risedronate in women with postmenopausal osteoporosis","volume":"75","author":"Mellstrom","year":"2004","journal-title":"Calcif. Tissue Int."},{"key":"10.1016\/j.maturitas.2017.04.008_bib0205","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1001\/jamainternmed.2014.1232","article-title":"Fracture prediction after discontinuation of 4\u20135 years of alendronate therapy. The FLEX study","volume":"174","author":"Bauer","year":"2014","journal-title":"JAMA Intern. Med."},{"key":"10.1016\/j.maturitas.2017.04.008_bib0210","doi-asserted-by":"crossref","first-page":"1910","DOI":"10.1002\/jbmr.2918","article-title":"Managing osteoporosis in patients on long-term bisphosphonate treatment: report of a Task Force of the American Society for Bone and Mineral Research","volume":"31","author":"Adler","year":"2016","journal-title":"J. Bone. Miner. Res."},{"issue":"Suppl. 2","key":"10.1016\/j.maturitas.2017.04.008_bib0215","doi-asserted-by":"crossref","first-page":"32","DOI":"10.3109\/13697137.2015.1099092","article-title":"Bisphosphonate drug holidays \u2212 when, why and for how long?","volume":"18","author":"Anagnostis","year":"2015","journal-title":"Climacteric"},{"key":"10.1016\/j.maturitas.2017.04.008_bib0220","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1002\/jbmr.1582","article-title":"Manitoba bone density program. does osteoporosis therapy invalidate FRAX for fracture prediction","volume":"27","author":"Leslie","year":"2012","journal-title":"J. Bone. Miner. Res"},{"issue":"Suppl. 3","key":"10.1016\/j.maturitas.2017.04.008_bib0225","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4158\/EP.16.S3.1","article-title":"American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for the diagnosis and treatment of postmenopausal osteoporosis","volume":"16","author":"Watts","year":"2010","journal-title":"Endocr. Pract."},{"key":"10.1016\/j.maturitas.2017.04.008_bib0230","article-title":"Severe rebound-associated vertebral fractures after denosumab discontinuation: nine clinical cases report","author":"Lamy","year":"2016","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.maturitas.2017.04.008_bib0235","doi-asserted-by":"crossref","DOI":"10.1007\/s00198-017-3919-1","article-title":"Observations following discontinuation of long-term denosumab therapy","author":"McClung","year":"2017","journal-title":"Osteoporos. Int."},{"key":"10.1016\/j.maturitas.2017.04.008_bib0240","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1002\/jbmr.1808","article-title":"Discontinuation of denosumab and associated fracture incidence: analysis from the fracture reduction evaluation of denosumab in osteoporosis every 6 months (FREEDOM) trial","volume":"28","author":"Brown","year":"2013","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.maturitas.2017.04.008_bib0245","doi-asserted-by":"crossref","first-page":"2383","DOI":"10.1007\/s00198-016-3535-5","article-title":"Hypercalcemia after discontinuation of long-term denosumab treatment","volume":"27","author":"Koldkj\u00e6r S\u00f8lling","year":"2016","journal-title":"Osteoporos. Int."},{"key":"10.1016\/j.maturitas.2017.04.008_bib0250","doi-asserted-by":"crossref","first-page":"4094","DOI":"10.1210\/jc.2014-1193","article-title":"A model of BMD changes after alendronate discontinuation to guide post alendronate BMD monitoring","volume":"99","author":"McNabb","year":"2014","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.maturitas.2017.04.008_bib0255","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.bone.2013.10.006","article-title":"Denosumab compared with risedronate in postmenopausal women suboptimally adherent to alendronate therapy: efficacy and safety results from a randomized open-label study","volume":"58","author":"Roux","year":"2014","journal-title":"Bone"},{"key":"10.1016\/j.maturitas.2017.04.008_bib0260","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1097\/AOG.0b013e318291718c","article-title":"Denosumab compared with ibandronate in postmenopausal women previously treated with bisphosphonate therapy: a randomized open-label trial","volume":"121","author":"Recknor","year":"2013","journal-title":"Obstet. Gynecol."},{"key":"10.1016\/j.maturitas.2017.04.008_bib0265","doi-asserted-by":"crossref","first-page":"e5496","DOI":"10.1097\/MD.0000000000005496","article-title":"The effect of sequential therapy forpostmenopausal women with osteoporosis. A PRISMA-compliant meta-analysis of randomized controlled trials","volume":"95","author":"Lou","year":"2016","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.maturitas.2017.04.008_bib0270","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1056\/NEJMoa022436","article-title":"The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis","volume":"350","author":"Meunier","year":"2004","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.maturitas.2017.04.008_bib0275","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1001\/jama.288.3.321","article-title":"Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial","volume":"288","author":"Rossouw","year":"2002","journal-title":"JAMA"},{"key":"10.1016\/j.maturitas.2017.04.008_bib0280","series-title":"European Medicines Agency Recommendation to Restrict the Use of Protelos\/Osseor (strontium Ranelate)","year":"2013"},{"key":"10.1016\/j.maturitas.2017.04.008_bib0285","doi-asserted-by":"crossref","first-page":"2769","DOI":"10.1007\/s00198-012-2093-8","article-title":"IOF CSA inadequate responders working group. Treatment failure in osteoporosis","volume":"23","author":"Diez-Perez","year":"2012","journal-title":"Osteoporos. Int."}],"container-title":["Maturitas"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0378512217305364?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0378512217305364?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T09:08:35Z","timestamp":1759914515000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0378512217305364"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,7]]},"references-count":57,"alternative-id":["S0378512217305364"],"URL":"https:\/\/doi.org\/10.1016\/j.maturitas.2017.04.008","relation":{},"ISSN":["0378-5122"],"issn-type":[{"value":"0378-5122","type":"print"}],"subject":[],"published":{"date-parts":[[2017,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Drug holidays from bisphosphonates and denosumab in postmenopausal osteoporosis: EMAS position statement","name":"articletitle","label":"Article Title"},{"value":"Maturitas","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.maturitas.2017.04.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}